2. Misfolded Protein
Protein/Ab Stability
Protein/Ab Secretion
Functional Protein
Immunogenicity
human cell
Polypeptide
Protein Folding
· Suppression of Translation
· Induction/Expression of Chaperones
· Cell suicide
Platform enhances Protein Production of the Target Proteins
by controlling Protein Folding/Cell Quality Control System
RNA
gene
Folded Protein
· Degradation of proteins Degradation
RNA
Protein Folding
Cell Quality Control System
human cell
Total yield of
Biologics/Ab
TAPBOOSTTAPBOOST®®
Protein Folding System and Quality ControlProtein Folding System and Quality Control
SystemSystem
3. Screening System
Step 1: in silico Screening for Protein Domain/Subdomain
Misfolding-Prone
Protein
Degradation
Poor Secretion
Protein Stability
Protein Secretion
Step 3
Protein Stability
and Secretion Test
Develop the technology which controls protein folding/cellular quality control system
specifically for an intended target protein
GOAL
Through the screening,
we discovered the amino
acid sequence with
protein stability and
secretion activity
First Year
Step 2: Library Construction
((TaTargetedrgeted PProteinrotein BoostBoosting Platform)ing Platform)
DiscoveryDiscovery
TAPBOOSTTAPBOOST®®
4. Development of Platform
Step 4: Construction of
Targeting domain
(bind to a target protein)
Discovered sequence
(Effecter Sequence)
Targeting Domain
• Fc binding sequence: 14 combinations
• Antibody binding sequence: 5 combinations
• Target specific sequence: 9 combinations
• Unfolding protein binding sequence: 5 combinations
Flexible Linker / Rigid Liner
• 5 combinations
Effecter Sequence
Signal Sequence
• 4 combinations
Targeted Protein
Second
Year
Step 5: Enhancement of the Production of
Target Protein by
PlatforPlatfor
mm
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
Golgi
ER
TAPBOOSTTAPBOOST®® ((TaTargetedrgeted PProteinrotein BoostBoosting Platform)ing Platform)
Discovery-2Discovery-2
5. Discovered sequence
Sequence Optimization
Deletion of
the sequence
(49 deletion mutants)
Minimum sequence
(9 amino acid sequence)
Step 6: Identification of the Minimum Sequence
Various mutants of the sequence
(49 mutations)
Step 7: Formulation of the Sequence
X1 X2 X3 X4 X5 X6 X7 X8 X9
Formulation of the Amino Acid Sequence
((TaTargetedrgeted PProteinrotein BoostBoosting Platform)ing Platform)
Discovery-3Discovery-3
TAPBOOSTTAPBOOST®®
6. Model Protein; IL-13 receptor α2 (IL13Rα2)-Fc fusion protein
CHALLENGE: The expression levels of
IL13Rα2 are poor, and the protein is
prone to misfolding and aggregation.
Cell
IL13Rα2-Fc
ERNu
• Disease Relevance: a key mediator of allergic inflammation
Aggregation of
IL13Rα2-Fc
Only properly folded
IL13Rα2-Fc secrets
• Fc fusion protein with sIL13Rα2 (sIL13Rα2-Fc) has been developed for the
treatment of asthma
• Production of sIL13Rα2-Fc using human cells is inefficient due to its
instability
• Soluble IL13Rα2 (sIL13Rα2) blocks the signal from IL-13 as a decoy
receptor
Application: IL13RApplication: IL13Rαα2-Fc Protein Case2-Fc Protein Case
StudyStudy
TAPBOOSTTAPBOOST®®
8. ER
Targeted Protein
Targeting Domain was designed
to bind only to Protein B
Secreted
Target Protein
(A or B)
A A A B B B B BTarget Protein
Platform: Target Protein SpecificityPlatform: Target Protein SpecificityTAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
specifically enhances the secretion of the
target proteins
TAPBOOSTTAPBOOST®®
B
9. enhances
the production of all three
tested antibodies
Antibody Production
Detection: Western Blot Assay using anti-hIgG antibody
Platform: Antibody ExamplesPlatform: Antibody ExamplesTAPBOOSTTAPBOOST®®
Western
(anti-hIgG Ab)
TAPBOOSTTAPBOOST®®
Target Antibody
anti-IL8 Ab
(DP12)
anti-TNFα Ab
(Humira)
anti-VEGF Ab
(Avastin)
antibody Brand Name
Production
Increase
(produced protein)
anti-IL8 Ab DP12 6.4 +/- 0.89
anti-TNFα Ab Humira 6.3 +/- 0.33
anti-VEGF Ab Avastin 3.5 +/- 0.27
TAPBOOSTTAPBOOST®®
10. Antibody binding affinity for its corresponding epitope
Detection: ELISA using rVEGF, rTNFα, or rIL-8 for Avastin, Humira, or DP12, respectively
Platform: Antibody ExamplesPlatform: Antibody ExamplesTAPBOOSTTAPBOOST®®
Antibodies produced
by
hold activity
TAPBOOSTTAPBOOST®®
anti-TNFα Ab
(Humira)
anti-VEGF Ab
(Avastin)
anti-IL8 Ab
(DP12)
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
0
1
2
3
4
5
6
7
8
0
1
2
3
4
5
6
7
8
FoldIncrease
Avastin
FoldIncrease
FoldIncrease
Humira DP12
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
antibody Brand Name
Production
Increase
(produced protein)
Production Increase
by ELISA
anti-VEGF Ab Avastin 3.5 +/- 0.27 4.2 +/- 0.19
anti-TNFα Ab Humira 6.3 +/- 0.33 6.0 +/- 0.82
anti-IL8 Ab DP12 6.4 +/- 0.89 7.3 +/- 0.56
12. 0
2
4
6
8
10
12
Foldincrease
TNFRI-Fc (IgG1)
TNFα Binding Ability (ELISA)
TNFRI-Fc (IgG4)
Platform: Fc Fusion of hIgG4Platform: Fc Fusion of hIgG4TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
enhances the production
of both types of Fc fusion protein
TAPBOOSTTAPBOOST®®
13. IL13Rα2-FcTNFRI-Fcα1AT-Fc α1ATMT-Fc
Original Secretion of
Targeted Protein
Effect of
Maximum
Effect
may “rescue” problem proteins from
misfolding and maximize secretion levels
works on difficult proteinsworks on difficult proteinsTAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
14. Protein Aggregation Experiment
conducted by Major Pharma Partner in Pilot Project
• PD group wanted to know whether can also results in lower aggregation.
CharacterizationCharacterization
TAPBOOSTTAPBOOST®®
reduces the aggregation
of produced proteins
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
15. Target Protein
(Conditioned Media)
FoldIncrease(%)
IL13Rα2-Fc
IL13Rα2-Fc
Protein Production in CHO Suspension conducted by CRO
0
50
100
150
200
250
300
350
400
450
enhances the production in CHO
Suspension Expression System
Transition from 293T to CHO suspensionTransition from 293T to CHO suspension
systemsystem
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
16. PKCActivity(OD450-BG)
AT1 receptor
-AT1 receptor
Angiotensin II (100nM) 5min 10min 15min 30min
Angiotensin II receptor type 1
(AT1 receptor)
AT1 receptor
-AT1 receptor
+ Angiontensin II
Application for Screening R&D – GPCR proteins (POC)Application for Screening R&D – GPCR proteins (POC)
enhances the expression of difficult-to-express
proteins such as GPCR proteins
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
17. Soluble protein (SP)
Inclusion Body (IB)
bacteria
Bacterial Genome
plasmid
We customized platform for bacterial
expression system by using a proprietary algorithms
and intensive search for specific amino acid
sequences involved in protein folding.
Platform
Test Protein A
Test Protein B
Test Protein C
SP IBTotal SP IBTotal
SP IBTotal SP IBTotal
SP IBTotal SP IBTotal
Application for Microbial ExpressionApplication for Microbial Expression
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
increases both expression and solubility of the
target protein in bacteria
TAPBOOSTTAPBOOST®®
18. Advantages of
SummarySummary
Increased Productivity byTarget proteins
TNFRI-Fc (Enbrel) 480%
Factor IX-Fc 320%
Factor FVII-Fc 1000%
IL13Rα2-Fc protein 2000%
Factor VIII-Fc 2100%
Humira
Avastin
DP12
600%
420%
730%
293T monolayer System
293T Suspension System
IL13Rα2-Fc protein 1100%
CHO Suspension System
IL13Rα2-Fc protein 400%
* Optimization process is in progress
*
*
(%)TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
• Any kind of protein can be expressed by platform
• Easy implementation into your current bioprocess
• Combine with any other technology for synergistic effect
TAPBOOSTTAPBOOST®®
TAPBOOSTTAPBOOST®®
Editor's Notes
Conceptual background on the challenge/opportunity of protein folding in recombinant protein expression systems. TAPBOOST’s solution to these challenges.
Our efforts at Boston strategics have focused on development of a value-added system using proprietary chaperone technology to optimize/improve folding.
In order to create a system that produces “clean” and natural untagged sequence we improved upon the original designs. This is now protected by global patents.
Conclusion: not only larger yields, but less aggregation: larger proportion of monomeric target.
The other Steps, transitions to CHO, and scale-up feasibilities are moving along with other partners.
GPCRs are a major class of therapeutically relevant molecules, representing more than 50% of all screening targets. Here we tested another application for the TapBoost platform- the use in producing difficult to express drug screening targets such as GPCRs.
Conclusion: not only larger yields, but less aggregation: larger proportion of monomeric target.
The other Steps, transitions to CHO, and scale-up feasibilities are moving along with other partners.